{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.46","value":"16.9"},{"groupId":"OG001","spread":"3.97","value":"4.9"}]}],"title":"CHQ-PF50 physical score"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.15","value":"6.2"},{"groupId":"OG001","spread":"2.49","value":"-1.1"}]}],"title":"CHQ-PF50 psychosocial score"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"description":"CHQ-PF50 measures HRQoL in children 5-18 years old from parent's perspective. Questionnaire completed by parent without input from patient. Total score ranges from 0-100. Increases in scores represent improved well-being in subjects as assessed by their parents. Mixed linear model on change from baseline in CHQ-PF50 score with treatment group, stratification factors, day of assessment and interaction between group and day as covariates. Covariance analysis used a repeated measures approach, so all timepoints over time were taken into account.","dispersionType":"Standard Error","groups":[{"description":"Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\\>37.5 kg) received two sc injections.","id":"OG000","title":"Canakinumab"},{"description":"Patients received a single dose matching placebo of canakinumab on day 1.","id":"OG001","title":"Placebo"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The Full Analysis Set (FAS) consisted of all randomized patients who received at least one dose of study drug. Observed cases only were analyzed.","reportingStatus":"POSTED","timeFrame":"Over 4 week study period (Baseline, Day 15, Day 29)","title":"Change in Health-related Quality of Life (HRQoL)Over Time by Use of the Child Health Questionnaire - Parent Form (CHQ-PF50)","type":"SECONDARY","unitOfMeasure":"units on a scale"}